Novartis announces 2,000 job losses, profits up

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

The firm said in a statement profits for the quarter were up 12 percent and that the job cuts were part of a $300 million restructuring programme to strengthen productivity.

Sales in the July through September period increased by 18% to $14.84 billion.

said it would begin consulting with employees on the modalities of the job cuts. The company said it would create 700 , mainly in countries with a lower cost base.

The cost-saving measures are to be spread over three to five years the company said. In the plan, Novartis expects to close one plant in Switzerland an another in Italy.

Research currently based in Switzerland would be transferred to the United States, Novartis said

After the earnings news, shares in Novartis fell by 0.97 percent Tuesday morning, in a market down by 0.30 percent.

add to favorites email to friend print save as pdf

Related Stories

Novartis says swine flu vaccine boosts profit

Jan 26, 2010

Swiss pharmaceutical group Novartis posted on Tuesday an 8.0-percent jump in core annual net profit for 2009, saying that business had been boosted by sales of swine flu vaccine.

Novartis says on track to deliver US vaccine order

Oct 29, 2009

(AP) -- Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.

SAP profits up strongly in third quarter

Oct 14, 2011

German software giant SAP said Friday its profits more than doubled in the third quarter thanks to strong sales and lower legal costs related to litigation with arch-rival Oracle.

Recommended for you

Hormonal therapy for transsexualism safe and effective

20 hours ago

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

23 hours ago

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments

More news stories

Laughing gas does not increase heart attacks

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...

Model recreates wear and tear of osteoarthritis

(Medical Xpress)—There's a reason osteoarthritis is often called wear-and-tear arthritis: Repeated stress on joints over time results in degeneration of the soft cartilage that normally distributes loads ...

Taxing unhealthy food spurs people to buy less

Labeling foods and beverages as less-healthy and taxing them motivates people to make healthier choices, finds a recent study in the American Journal of Preventive Medicine. When faced with a 30 percent tax on ...

New technologies for retinal therapies

The future of the investigation and treatment of retinal disorders is already here at the MedUni Vienna: in the new Christian Doppler "OPTIMA" (Ophthalmic Image Analysis) laboratory headed by Ursula Schmidt-Erfurth, ...

Protalix signs supply deal with Brazilian govt

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...